HWHG(SH:600079) Zheng Quan Zhi Xing·2025-07-10 10:11Core Viewpoint - The report outlines the equity changes of Renfu Pharmaceutical Group Co., Ltd., detailing the involvement of various stakeholders and the establishment of a concerted action relationship between the parties involved to stabilize the company's management and promote its development [24][25]. Group 1: Equity Change Overview - The equity change involves the concerted action relationship established between招商生命科技 (Wuhan) Co., Ltd. and 武汉高科国有控股集团有限公司, allowing them to collectively hold 429,276,816 shares of Renfu Pharmaceutical, representing 26.30% of the total share capital [27][29]. - Prior to this change, the combined holdings of the involved parties were 403,089,608 shares, accounting for 24.70% of the total share capital [26][28]. Group 2: Stakeholder Information - 招商生命科技 holds 114,255,773 shares directly, equating to a 7.00% stake, while the other parties include 生科投资发展 with 97,933,558 shares (6.00%), 春泥 1号 with 190,900,277 shares (11.70%), and 武汉高科 with 26,187,208 shares (1.60%) [28]. - The report confirms that the stakeholders have not changed their respective shareholding percentages as a result of this equity change [27]. Group 3: Purpose and Future Plans - The primary purpose of this equity change is to stabilize the management of Renfu Pharmaceutical and enhance its governance structure, thereby improving asset quality and ensuring healthy development [25]. - 招商生科 plans to increase its holdings in Renfu Pharmaceutical by at least 1% and no more than 2% within six months following the announcement of the increase plan, with a maximum purchase price set at 25.53 RMB per share [25][26].